Management of bone metastases in patients with castration-resistant prostate cancer

Urol Int. 2014;92(4):377-86. doi: 10.1159/000358258. Epub 2014 Apr 30.

Abstract

Bone metastases are a very common problem in prostate cancer. They are associated with considerable morbidity, adversely affect quality of life and frequently lead to advanced bone events (so-called skeletal-related events, SREs); SREs include fractures, spinal cord compression and the requirement for bone surgery or bone radiation. The aim of this paper was to evaluate currently available treatment options in the prevention and management of SREs and bone metastases in men with castration-resistant prostate cancer and to outline the importance of interdisciplinary management strategies. It also discusses the diagnostic workup of osseous metastases and practical considerations for the utilization of bone-targeted therapies in accordance with current guidelines to provide a consensus for special and/or difficult clinical situations.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / pathology
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / therapy*
  • Bone and Bones / pathology*
  • Denosumab
  • Diphosphonates / therapeutic use
  • Humans
  • Imidazoles / therapeutic use
  • Interdisciplinary Communication
  • Male
  • Medical Oncology / standards
  • Neoplasm Metastasis
  • Prostatic Neoplasms, Castration-Resistant / pathology*
  • Quality of Life
  • Spinal Cord Compression
  • Treatment Outcome
  • Zoledronic Acid

Substances

  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Denosumab
  • Zoledronic Acid